REGENXBIO Inc. (Nasdaq: RGNX) today announced it will initiate a pivotal Phase IIb/III clinical trial for investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) ...

With an increased focus on proactive care, Intermountain Health has made significant strides in the past year to expand ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The prevalence of cataract, responsible for 66.2% of blindness cases, and the silent rise of glaucoma (affecting 12 million ...

Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who used semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA).

From eye fatigue to headaches, you may be missing signs your eye power has changed, mistaking them as stress, exhaustion or something else.

REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the second quarter ended June 30, 2025.

Zepbound approved for treating moderate to severe obstructive sleep apnea in adults with obesity, showing improvement in ...

Optomed Plc Stock Exchange Release 7 August 2025 at 9.30 pm, Helsinki. Optomed's financial reporting in 2026. Optomed Plc will release its Financial Statement Bulletin, Half-Year ...

Revenio Group Corporation | Stock Exchange Release | August 07, 2025 at 09:00:00 EEST Net sales and profit development at a good level in a challenging business environmentThis release is a summary of ...

Healthy snacks for people with diabetes satisfy hunger while helping lower blood sugar. Next time you’re in a hurry, try one ...

A new study finds cuts in copay assistance for retina injections are harming lower-income communities and leading to poorer ...